Impact of Recombinant Human Growth Hormone on HIV Persistence
A Proof-of-concept Study to Assess the Effect of Recombinant Human Growth Hormone on the Size of the Replication-competent Viral Reservoir in HIV-infected Individuals on Suppressive Antiretroviral Therapy
Sponsor: EMD Serono
This PHASE2 trial investigates Growth Hormone Treatment and Human Immunodeficiency Virus and is currently completed. EMD Serono leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Oct 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
▶ Show 6 earlier versions
-
Oct 2021 — Apr 2023 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Jul 2019 — Oct 2019 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Jul 2019 [monthly]
Recruiting PHASE2
-
Apr 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- EMD Serono
- McGill University Health Centre/Research Institute of the McGill University Health Centre
For direct contact, visit the study record on ClinicalTrials.gov .